Cory berkland.

Calcium-crosslinked LABL-TAT complexes effectively target gene delivery to ICAM-1 expressing cells Supang Khondee1, Abdulgader Baoum1, Teruna J. Siahaan1, and Cory Berkland1,2,* 1Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS 66047 2Department of Chemical and Petroleum Engineering, The …Our clinical studies will determine if BBI-001 can reduce or eliminate the need for lifelong phlebotomies in Hereditary Hemochromatosis patients," said Dr. Cory Berkland, Bond's CEO, Chairman ...Cory Berkland PhD, University of Illinois, 2003 MS, University of Illinois, 2001 BS, Iowa State University, 1998 View All People contact info: Email: [email protected] The Berkland lab focuses on developing new therapeutics and biomaterials for improving human health3307145. Contact Us About The Company Profile For Kinimmune, Inc. KINIMMUNE, INC. KANSAS FOREIGN FOR-PROFIT. WRITE REVIEW. Address: Cory Berkland 1117 E. 1264 Road Lawrence, KS 66947. Registered Agent: Cory Berkland.

Cory J. Berkland [email protected] Department of Chemical and Petroleum Engineering, University of Kansas, 1530 West 15th Street, Lawrence, KS, 66045 USA. Department of Pharmaceutical Chemistry, University of Kansas, 2095 Constant Avenue, Lawrence, KS, 66047 USA. E-mail: [email protected] Search for more papers by this author

Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. He is also a …Joshua O Sestak 1 , Bradley P Sullivan 1 , Sharadvi Thati 1 , Laura Northrup 1 , Brittany Hartwell 2 , Lorena Antunez 1 , M Laird Forrest 1 , Charlotte M Vines 3 , Teruna J Siahaan 1 , Cory Berkland 4

Modeling release of small molecules from degradable microspheres is important to the design of controlled-release drug delivery systems. Release of small molecules from poly(d,l-lactide-co-glycolide) (PLG) particles is often controlled by diffusion of the drug through the polymer and by polymer degradation.Ruolin Lu, 1 Chad Groer, 2 Peter A. Kleindl, 1 K. Ryan Moulder, 1 Aric Huang, 1 Jordan R. Hunt, 1 Shuang Cai, 1, 2 Daniel J. Aires, 2, 3 Cory Berkland, 1 and Laird Forrest 1, 2, * Ruolin Lu 1 Department of Pharmaceutical Chemistry, University of Kansas, Lawrence, Kansas1. Introduction. Fixed dose combinations (FDCs) are defined as a combination of two or more active ingredients within a single form of pharmaceutical administration [Citation 1 – Citation 6].They have been shown to appreciably reduce the risk of medication non-adherence, which is particularly important in patients with chronic diseases [Citation …BERKLAND CORY. Author information. Affiliations. All authors. 1. KIM KYEKYOON Patent: Reexamination Certificate Second Reexamination - United States Application: US20030624029 on 21 Jul 2003 Publication: 21 Jul 2003 PAT: US7368130 . Patent. Share this article ...Cory Berkland joins the faculty Nov. 1 from The University of Kansas, where he is the Solon E. Summerfield Distinguished Professor of Chemical and Petroleum Engineering and Pharmaceutical Chemistry. He has been on the faculty since 2003. In addition, he is the cofounder, chair and CEO of Bond Biosciences based in the Kansas City area; co ...

How it works: Cory Berkland, Ph.D., professor at the University of Kansas, is a serial entrepreneur, co-founding Orbis Biosciences, Savara Pharmaceuticals and Orion Biosciences, as well as co-developing several technologies with industry partners. In late 2012, IAMI invested in novel polymer technology discovered by Dr. Berkland with the intent ...

Senior Research Scientist. (217) 244-6345. [email protected]. 2050 ECE Building. Teaching. ECE 110 - Introduction to Electronics.

Cory Berkland. The Berkland Lab investigates pharmaceuticals and biomaterials. They aim to understand the transport of pharmaceuticals as a function of physical and chemical properties. Biomaterials are also investigated for applications in regenerative medicine. Faculty Profile. Berkland Research Lab.Bond Biosciences has a strong board and managment team with significant industry experience including Cory Berkland, Mike Riley, Tim Opler and Mike Beckloff.09-Nov-2020. Durham, NC. 00000000. Evecxia. Executive Director Operations. 09-Nov-2020. Durham, NC. Information on current and former positions, network members and contacts for Dexter Pearson. Use the PitchBook Platform to explore the full profile.The most recent tenant is Cheryl Kootman.Past residents include Jodi Berkland, Cory Berkland, Marc Kootman, Branch Metal Processing and Jonathan Kootman.FastPeopleSearch results provide address history, property records, and contact information for current and previous tenants.Cory Berkland is a founder of, and advisor to, Orbis Biosciences, Inc. and Savara Pharmaceuticals, Inc. Additionally, both Cory Berkland and Mark Bailey are named as inventors on patents and/or patent applications relating to technologies described in this article. Part of this work was supported by NIH grants R03 AR054035 and P20 RR016443.

Introduction. Fibroblast growth factor-10 (FGF-10), also known as keratinocyte growth factor-2 (KGF-2), is a 208 amino acid polypeptide (M w 19,000) belonging to the FGF family. These structurally related proteins bind to polyanions including heparin and are involved in a variety of physiological and pathological processes [].FGF-10 activities include epithelial cell proliferation and ...He received MS and PhD degrees from the Department of Chemical and Biomolecular Engineering at the University of Illinois in Urbana-Champaign and a BS degree in Chemical Engineering from Iowa State University in Ames. Prof. Berkland is a co-founder of Orbis Biosciences, Savara Pharmaceuticals, Bond Biosciences and Orion BioScience. Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors . Pharmaceutical Research . 2003 Jul 1;20(7):1055-1062. doi: 10.1023/A:1024466407849Title: Stable curcumin-loaded polymeric micellar formulation for enhancing cellular uptake and cytotoxicity to FLT3 overexpressing EoL-1 leukemic cellsCorresponding Author. Cory Berkland. [email protected]; Department of Pharmaceutical Chemistry, The University of Kansas, Lawrence, KS, 66047 USA. E-mail: [email protected]; [email protected] Search for more papers by this authorCory Berkland, Ph.D. Abstract Basic principles have emerged for oral and intravenous drug design, but fewer efforts have ... Berkland is a co-founder of Orbis Biosciences (purchased by Adare Pharmaceuticals), Savara Pharmaceuticals (NASDAQ: SVRA), Bond Biosciences, and Orion BioScience. Title: Microsoft Word - Cory Berkland Seminar Announcement ...

Alhakamy, Nabil A; Nigatu, Adane S; Berkland, Cory J et al. (2013) Noncovalently associated cell-penetrating peptides for gene delivery applications. Ther Deliv 4:741-57 Alhakamy, Nabil A; Berkland, Cory J (2013) Polyarginine molecular weight determines transfection efficiency of calcium condensed complexes. Mol Pharm 10:1940-8Na Zhang; Chuda Chittasupho; Chadarat Duangrat; Teruna J. Siahaan; Cory Berkland: 1-May-2017: Stable curcumin-loaded polymeric micellar formulation for enhancing cellular uptake and cytotoxicity to FLT3 overexpressing EoL-1 leukemic cells: Singkome Tima; Songyot Anuchapreeda; Chadarat Ampasavate; Cory Berkland; Siriporn Okonogi

I would like to sincerely and gratefully thank my advisor, Dr. Cory Berkland, for all of his support, guidance, patience, understanding, and most importantly, his friendship during my graduate studies at The University of Kansas. I have been fortunately blessed to have an advisor who gave me a great opportunity to develop my own individuality byBrad Spitz, Nathan Dormer & Cory Berkland are part of Orbis Biosciences leadership, Maria Stecklein Flynn is the CEO.Cory Berkland is a professor of pharmaceutical chemistry and chemical and petroleum engineering at the University of Kansas. (Berkland Tr. 593) The Court recognized Dr. Berkland as an expert in the preparation and analysis of pharmaceutical formulations.Chuda Chittasupho, Sheng-Xue Xie, Abdulgader Baoum, Tatyana Yakovleva, Teruna J. Siahaan, Cory J. Berkland. ICAM-1 targeting of doxorubicin-loaded PLGA nanoparticles to lung epithelial cells. European Journal of Pharmaceutical Sciences 2009, 37 (2) , 141-150.The objective of this work is to use colloidal gel from alginate-chitosan-PLGA complex to deliver Ac-PLP-BPI-NH 2-2 peptide in a controlled-release manner as a vaccine-like therapeutic to suppress experimental autoimmune encephalomyelitis (EAE) in the mouse model.Oppositely charged PLGA nanoparticles were prepared by a solvent diffusion method.1. Introduction. Injectable scaffolds have received attention due to their potential for avoiding the invasive surgery typically required for tissue implantation. 1 From a clinical perspective, the use of injectable materials is an attractive alternative to surgery as it reduces the risk of infection, scar formation, patient discomfort and the cost of treatment. …Brittany L. Hartwell, Aaron Smalter Hall, David Swafford, Bradley P. Sullivan, Aaron Garza, Joshua O. Sestak, Laura Northrup, and Cory Berkland. Molecular Dynamics of Multivalent Soluble Antigen Arrays Support a Two-Signal Co-delivery Mechanism in the Treatment of Experimental Autoimmune Encephalomyelitis.Cory Berkland, Corresponding Author. [email protected]; Department of Chemical and Petroleum Engineering, The University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047. Department of Pharmaceutical Chemistry, The University of Kansas, 2030 Becker Drive, Lawrence, Kansas 66047.El-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26:1752–1763. [PMC free article] [Google Scholar] El-Gendy N, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009; 98:2731–2746.Cory Berkland’s lab studies pharmaceuticals and biomaterials with a particular emphasis on molecular design, drug formulation, and transport in the human body. Professor …

Abstract. Lung surfactant is crucial for optimal pulmonary function throughout life. An absence or deficiency of surfactant can affect the surfactant pool leading to respiratory distress. Even if the coupling between surfactant dysfunction and the underlying disease is not always well understood, using exogenous surfactants as replacement is ...

That effort led to an NIH grant with Cory Berkland, Ph.D., of the University of Kansas, as principal investigator. Flash forward to present day and Detamore is a principal investigator of this current NIH project. Berkland, Dr. Brian Andrews, a surgeon who specializes in head and neck surgery at the University of Iowa Hospitals and Clinics, and ...

I would like to sincerely and gratefully thank my advisor, Dr. Cory Berkland, for all of his support, guidance, patience, understanding, and most importantly, his friendship during my graduate studies at The University of Kansas. I have been fortunately blessed to have an advisor who gave me a great opportunity to develop my own individuality bySingh M, Morris CP, Ellis RJ, Detamore MS, Berkland C. Microsphere-Based Seamless Scaffolds Containing Macroscopic Gradients of Encapsulated Factors for Tissue Engineering. Tissue Eng Part C Methods. 2008; 14:299–309. [Europe PMC free article] [Google Scholar]Cory Berkland Solon E. Summerfield Distinguished Professor School of Pharmacy, Pharmaceutical Chemistry Contact Info Email: [email protected] Phone: 785-864-1455 320E Multidisciplinary Research Building Lawrence 2030 Becker Drive Lawrence, KS 66047 Personal Links Cory Berkland Research Education —BERKLAND CORY. Author information. Affiliations. All authors. 1. KIM KYEKYOON Patent: Reexamination Certificate Second Reexamination - United States Application: US20030624029 on 21 Jul 2003 Publication: 21 Jul 2003 PAT: US7368130 . Patent. Share this article ...Dr. Cory J. Berkland Dr. Donna Pacicca June 17, 2014 Date defended. ii ACCEPTANCE PAGE ACCEPTANCE PAGE The Thesis Committee for Amanda Sutherland certifies that this is the approved version of the following dissertation: Decellularized Cartilage as a Bioactive Biomaterial for Cartilage TissueEl-Gendy N, Berkland C. Combination chemotherapeutic dry powder aerosols via controlled nanoparticle agglomeration. Pharm Res. 2009; 26:1752–1763. [PMC free article] [Google Scholar] El-Gendy N, et al. Budesonide nanoparticle agglomerates as dry powder aerosols with rapid dissolution. J Pharm Sci. 2009; 98:2731–2746.Cory Berkland has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vines CM, Berkland C. Hyaluronic acid graft polymers displaying peptide antigen modulate dendritic cell response in vitro. Mol Pharm. 2013;11(1):367-73. doi: 10.1021/mp4003909. [Europe PMC free article]

Chittasupho C, Sestak J, Shannon L, Siahaan TJ, Vines CM, Berkland C. Hyaluronic acid graft polymers displaying peptide antigen modulate dendritic cell response in vitro. Mol Pharm. 2013;11(1):367–73. doi: 10.1021/mp4003909. [Europe PMC free article]Cory Berkland View For the in vitro release experiment, 50 µl of UM-3003 adsorbed alhydrogel formulation was mixed with 500 µl of adjuvant-free human plasma in a closed glass vial at 37 °C and ...Acute B-Cell Inhibition by Soluble Antigen Arrays is Valency-Dependent and Predicts Immunomodulation in Splenocytes J. Daniel Griffin1, Martin A. Leon2, Jean R. Salash3, Michael Shao4, Brittany L. Hartwell1, Chad J. Pickens3, Joshua O. Sestak3, Cory Berkland1,3,4 1Bioengineering Graduate Program, University of Kansas, Lawrence, KS 2Department of Chemistry, University of Kansas, Lawrence, KSensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely. HHS Author Manuscripts. Nanoparticles of PLG have been widely studied for their use in drug delivery. 8600 Rockville Pike Bethesda, MD 20894. HHS Vulnerability Disclosure.Instagram:https://instagram. did bill self retire30 percent of 2000 dollarsdingier crossword cluedid wsu win today Professor Berkland is currently CEO of Bond Biosciences and is an executive and chairman of the board for Kinimmune and Axioforce. The Berkland lab focuses on developing new therapeutics and biomaterials for improving human health."We are pleased to begin this first-in-human clinical trial of our lead non-absorbed oral therapy and thankful for the seasoned development team that contributed to this significant milestone," said Dr. Cory Berkland, Bond's CEO, Chairman of the Board and Co-founder. social strengthscraigslist auto inland empire 2.1. Determination of Cytotoxicity of Doxorubicin (Dox), Idarubicin (Ida), and Curcumin (Cur) on Leukemic Cell Viability by MTT Assay. A cell viability curve demonstrated Dox (Figure 1 A) and IDa (Figure 1 B) exhibited the highest cytotoxicity for EoL-1 cells, followed by U937, KG-1, and KG-1a cells.The cytotoxicity of all the treatments was assessed using an inhibitory concentration at a 50% ... zillow cheektowaga ny for rent The objective of this work is to use colloidal gel from alginate-chitosan-PLGA complex to deliver Ac-PLP-BPI-NH 2-2 peptide in a controlled-release manner as a vaccine-like therapeutic to suppress experimental autoimmune encephalomyelitis (EAE) in the mouse model.Oppositely charged PLGA nanoparticles were prepared by a solvent diffusion method.Berkland C, Kim K, Pack DW. PLG microsphere size controls drug release rate through several competing factors . Pharmaceutical Research . 2003 Jul 1;20(7):1055-1062. doi: 10.1023/A:1024466407849